Nocturia, Benign Prostatic Hyperplasia
Conditions
Keywords
Benign prostatic hyperplasia, Nocturia, Silodosin, Thrupas
Brief summary
The objective of this study is to determine safety and efficacy of silodosin, which is a treatment for benign prostatic hyperplasia with high selectivity to α1A-receptor, on patients with benign prostatic hyperplasia accompanied by nocturia.
Detailed description
This study is designed as a multi-center, prospective, open-label and single-arm study. Subjects who are willing to provide written informed consent will be enrolled after screening for eligibility criteria. The subjects will be administered with investigational product for 12 weeks and visit as outpatients for evaluation of safety and efficacy at baseline (visit 2) and 4 weeks (visit 3) and 12 weeks (visit 4) after baseline.
Interventions
DRUGSilodosin
OTHERLaboratory tests
Subject's overall health state will be evaluated by clinical laboratory tests. Serum chemistry test: Creatinine, Blood Urea Nitrogen(BUN), Aspartate aminotransferase(AST), Alanine aminotransferase(ALT) Urinalysis: Urine Specific Gravity, Urine pH, Urine Protein, Urine Glucose, Urine Ketone, Urine Bilirubin, Urine Urobilinogen, Urine Nitrite, Urine Occult Blood(OB), Urine Red Blood Cell(RBC), Urine White Blood Cell(WBC) Immunoassay: Prostate Specific Antigen(PSA)
OTHER3-days voiding diary
3-day voiding diaries will be distributed on Visits 1, 2 and 3. Subjects will record incidence of nocturia during 3 days on the diaries within 7 days of Visits 2 (baseline), 3 and 4. The average will be used to confirm the change in incidence of nocturia (at baseline, results from within 1 week from screening may be used but will be excluded for subjects needing wash-out period).
OTHER12 weeks
Sponsors
JW Pharmaceutical
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Males of at least 50 years of age, with current diagnosis of benign prostatic hyperplasia * Symptoms of nocturia evidenced by ≥2 episodes per night in average according to 3-day voiding diary * More than total of 8 points on IPSS and 3 points on QoL * Able to provide written informed consent and to comply with all study procedures
Exclusion criteria
* PSA level \> 10 ng/㎖ (except patients who had 4 ng/㎖ \< PSA level ≤ 10 ng/㎖ 6 months prior to screening and identified as negative from biopsy) * Symptoms of postural hypotension * Severe renal disorders or creatinine clearance ≥ 2.0 mg/dL * Severe hepatic disorders or AST or ALT ≥ 3 x upper limit of normal (ULN) * Severe cardiac disorders or development or diagnosis of vascular disorder (unstable angina, myocardial infarction, cerebral infarction, cerebral hemorrhage, coronary artery bypass graft, etc) 6 months prior to enrollment * Any disorder of the gastrointestinal system which could result in altered digestion or absorption, history of gastrointestinal tract surgery except ecphyadectomy * Patients with bladder cancer, cystolith or urethral stricture * Patients with neurogenic bladder * History of acute urinary retention * Indwelling catheter or self intermittent catheterization * Patients with pyuria 1 month prior to screening * History of prostatic cancer * History of prostatic surgery * Patients with uncontrolled chronic disease * Alcoholism or sustained drug dependent abuse 1 year prior to screening * Hypersensitivity to α1A-receptor blockers * Administration of following drugs within according periods prior to screening - 2 weeks: Antimuscarinic agents (Tolterodine, Trospium, Solifenacin, Fesoterodine, Propiverine, Oxybutynin, Flavoxate, etc), Anticholinesterase agents (Neostigmine methylsulfate, etc), Cholinergic agonists (Bethanechol Cl, etc), Benign prostatic hyperplasia agents (Tamsulosin HCl, Prazosin HCl, Terazosin HCl, Doxazosin mesylate, Silodosin, Naftopidil, etc), Tricyclic antidepressants (Amitriptyline, Clomipramine, Dosulepin, Doxepin, Imipramine, Quinupramine, etc), 6 months: 5-α-Reductase Inhibitors (Finasteride, Dutasteride) * Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of nocturia | 12 weeks | Descriptive statistics for incidence of nocturia will be provided for each visit. Paired t-test or Wilcoxon's signed rank test will be used for assessment of change from baseline to after 12 weeks of treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean change in Quality of Life(QoL) scores from baseline | 12 weeks | Descriptive statistics for secondary efficacy outcome measures will be provided for each visit. Assessment will be performed on whether the change from baseline to after 12 weeks of treatment has difference. For successive data, paired t-test or Wilcoxon's signed rank test will be used for assessment of change from baseline to after 12 weeks of treatment. |
| Mean change in Overactive Bladder Symptom Score(OABSS) from baseline | 12 weeks | Descriptive statistics for secondary efficacy outcome measures will be provided for each visit. Assessment will be performed on whether the change from baseline to after 12 weeks of treatment has difference. For successive data, paired t-test or Wilcoxon's signed rank test will be used for assessment of change from baseline to after 12 weeks of treatment. |
| Mean change in International Consultation on Incontinence modular Questionnaire-Nocturia(ICIQ-N) from baseline | 12 weeks | Descriptive statistics for secondary efficacy outcome measures will be provided for each visit. Assessment will be performed on whether the change from baseline to after 12 weeks of treatment has difference. For successive data, paired t-test or Wilcoxon's signed rank test will be used for assessment of change from baseline to after 12 weeks of treatment. |
| Mean change in Questions 3, 5 and 6 (voiding symptoms) of IPSS from baseline | 12 weeks | Descriptive statistics for secondary efficacy outcome measures will be provided for each visit. Assessment will be performed on whether the change from baseline to after 12 weeks of treatment has difference. For successive data, paired t-test or Wilcoxon's signed rank test will be used for assessment of change from baseline to after 12 weeks of treatment. |
| Mean change in International Prostate Symptom Score(IPSS) from baseline | 12 weeks | Descriptive statistics for secondary efficacy outcome measures will be provided for each visit. Assessment will be performed on whether the change from baseline to after 12 weeks of treatment has difference. For successive data, paired t-test or Wilcoxon's signed rank test will be used for assessment of change from baseline to after 12 weeks of treatment. |
| Mean change in Questions 2, 4 and 7 (storage symptoms) from baseline | 12 weeks | Descriptive statistics for secondary efficacy outcome measures will be provided for each visit. Assessment will be performed on whether the change from baseline to after 12 weeks of treatment has difference. For successive data, paired t-test or Wilcoxon's signed rank test will be used for assessment of change from baseline to after 12 weeks of treatment. |
| Ratio of subjects with ≥ 25% decrease in incidence of nocturia | 12 weeks | — |
| Ratio of subjects with ≥ 25% decrease in IPSS | 12 weeks | — |
| Mean change in Question 1 (postvoiding symptoms) of IPSS from baseline | 12 weeks | Descriptive statistics for secondary efficacy outcome measures will be provided for each visit. Assessment will be performed on whether the change from baseline to after 12 weeks of treatment has difference. For successive data, paired t-test or Wilcoxon's signed rank test will be used for assessment of change from baseline to after 12 weeks of treatment. |
Countries
South Korea
Outcome results
None listed